Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.

Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):461-6.

PMID:
26722082
2.

CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.

Sone K, Oguri T, Nakao M, Kagawa Y, Kurowaka R, Furuta H, Fukuda S, Uemura T, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Maeno K, Ito Y, Sato H, Muramatsu H, Niimi A.

Anticancer Res. 2017 Feb;37(2):935-939.

PMID:
28179355
3.

The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Sep;34(9):5193-8. Erratum in: Anticancer Res. 2014 Nov;34(11):6859. Anticancer Res. 2014 Dec;34(12):7485.

PMID:
25202114
4.

Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.

Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E.

Chest. 1995 Jul;108(1):163-9.

PMID:
7541742
5.

Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.

Holdenrieder S, Von Pawel J, Duell T, Feldmann K, Raith H, Schollen A, Nagel D, Stieber P.

Anticancer Res. 2010 May;30(5):1855-62.

PMID:
20592392
6.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

7.

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Jun;34(6):3205-10.

PMID:
24922695
8.

Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.

Pujol JL, Boher JM, Grenier J, Quantin X.

Lung Cancer. 2001 Feb-Mar;31(2-3):221-31.

PMID:
11165401
9.
10.

Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.

Cho A, Hur J, Hong YJ, Lee HJ, Kim YJ, Hong SR, Suh YJ, Im DJ, Kim YJ, Lee JS, Shim HS, Choi BW.

Tumour Biol. 2016 Mar;37(3):3205-13. doi: 10.1007/s13277-015-4034-6. Epub 2015 Oct 2.

PMID:
26432331
11.

Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.

Arrieta O, Villarreal-Garza C, Martínez-Barrera L, Morales M, Dorantes-Gallareta Y, Peña-Curiel O, Contreras-Reyes S, Macedo-Pérez EO, Alatorre-Alexander J.

BMC Cancer. 2013 May 22;13:254. doi: 10.1186/1471-2407-13-254.

12.
13.

Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.

Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M.

J Thorac Oncol. 2009 Dec;4(12):1530-6. doi: 10.1097/JTO.0b013e3181b9e608.

14.

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.

Lung Cancer. 2011 Oct;74(1):132-8. doi: 10.1016/j.lungcan.2011.01.024. Epub 2011 Mar 1.

PMID:
21367480
16.

Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.

Muley T, Dienemann H, Ebert W.

Anticancer Res. 2003 Sep-Oct;23(5b):4085-93.

PMID:
14666606
17.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
18.

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.

Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, Pilotto S, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A.

Lung Cancer. 2015 Jun;88(3):319-24. doi: 10.1016/j.lungcan.2015.03.016. Epub 2015 Apr 1.

20.

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.

Shukuya T, Ko R, Mori K, Kato M, Yagishita S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, Takahashi K.

Cancer Chemother Pharmacol. 2015 Oct;76(4):771-6. doi: 10.1007/s00280-015-2843-3. Epub 2015 Aug 11.

PMID:
26259641

Supplemental Content

Support Center